What is the role of the Jon Levine Family Trust in MariMed (MRMD) share ownership?

The Jon Levine Family Trust holds 6,684,640 MariMed common shares for the benefit of his spouse and children. Levine disclaims beneficial ownership of these trust-held securities, meaning they are reported but not treated as his personal beneficial holdings.

MariMed (MRMD) CEO Jon Levine logs RSU vesting and tax share withholding

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MariMed Inc. President and CEO Jon R. Levine reported equity compensation activity involving restricted stock units and common shares. He exercised 23,333 restricted stock units into 23,333 shares of common stock at a stated price of $0.0000 per share, reflecting a derivative exercise/conversion.

To cover tax withholding obligations from this RSU vesting, 8,085 common shares were withheld at $0.0840 per share, leaving him with 21,151,448 shares of common stock held directly after these transactions. An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.

Insider Trade Summary

23,333 shares exercised/converted

Mixed 4 txns

Insider Levine Jon R

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units (RSU)	23,333	$0.00	--
Exercise	Common stock	23,333	$0.00	--
Tax Withholding	Common stock	8,085	$0.084	$679.14
holding	Common stock	--	--	--

Holdings After Transaction: Restricted Stock Units (RSU) — 0 shares (Direct); Common stock — 21,159,533 shares (Direct); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)

Footnotes (1)

RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These RSUs were granted on March 7, 2023; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

03/09/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Jon R

(Last)

(First)

(Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD,

02062

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	03/07/2026		M		23,333	A	$0⁽¹⁾	21,159,533	D
Common stock	03/07/2026		F		8,085⁽²⁾	D	$0.084	21,151,448	D
Common stock								6,684,640	I	By the Jon Levine Family Trust⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units (RSU)	⁽¹⁾	03/07/2026		M			23,333	⁽⁴⁾	⁽⁴⁾	Common Stock, par value $.001 per share	23,333	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

4. These RSUs were granted on March 7, 2023; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Jon R. Levine	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did MariMed (MRMD) CEO Jon R. Levine report in this Form 4?

Jon R. Levine reported vesting of restricted stock units converting into 23,333 MariMed common shares and a related tax share withholding. These entries reflect equity compensation activity and not an open-market purchase or sale of MRMD stock.

How many MariMed (MRMD) shares did Jon R. Levine receive from RSU vesting?

He received 23,333 MariMed common shares through the exercise of 23,333 restricted stock units on a one-for-one basis. The transaction was recorded at a stated price of $0.0000 per share, consistent with equity award vesting mechanics.

Why were 8,085 MariMed (MRMD) shares disposed of in this filing?

The 8,085 MariMed common shares were withheld to satisfy tax withholding obligations arising from the RSU vesting. This tax-withholding disposition is recorded at $0.0840 per share and does not represent an open-market sale initiated for investment reasons.

How many MariMed (MRMD) shares does Jon R. Levine hold directly after these transactions?

After the RSU conversion and tax share withholding, Jon R. Levine directly holds 21,151,448 shares of MariMed common stock. This figure reflects his direct ownership only and excludes any shares held indirectly through family trusts.

Do the reported MariMed (MRMD) transactions indicate open-market buying or selling by the CEO?

No, the reported transactions involve RSU vesting converting into common shares and shares withheld for taxes. They are equity compensation and tax-related entries rather than discretionary open-market purchases or sales of MariMed stock by the CEO.